The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials
The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials
A consistent system for reporting adverse events (AEs) is paramount in cancer clinical trials and is crucial to ensure the safety and tolerability of chemotherapy. The shift towards individualized medicine in oncology over the last decade has brought with it an impressive array of novel, targeted therapies and increasingly complex …